Brain Imaging and Neuroimaging Market Size, Share, and Growth Forecast 2026 - 2033

The global brain imaging and neuroimaging market is expected to be valued at US$ 15.9 billion in 2026 and is projected to reach US$ 22.2 billion by 2033, growing at a CAGR of 4.9% between 2026 and 2033.

Market growth is driven primarily by the rising global burden of neurological disorders, making accurate and early brain imaging essential for diagnosis, treatment selection, and therapy monitoring. A Global Burden of Disease (GBD) analysis published in The Lancet Neurology in 2024 found that neurological conditions affected 3.4 billion people, or 43% of the world's population, in 2021, making them the leading cause of ill health globally. The World Health Organization (WHO) estimates that 57 million people were living with dementia in 2021, while the World Stroke Organization (WSO) reports more than 12 million new strokes each year.

The approval of anti-amyloid therapies for Alzheimer's disease, which require amyloid confirmation and MRI safety monitoring, is creating additional imaging demand. Advances in artificial intelligence (AI), PET tracers, and helium-efficient MRI systems are expected to sustain growth through 2033.

Drivers - Rising Global Burden of Stroke, Dementia, and Neurological Disorders

The growing prevalence of neurological diseases is a major driver of brain imaging demand. Stroke remains one of the leading causes of death and disability worldwide; the World Stroke Organization reports more than 12 million new strokes and about seven million stroke deaths annually, and rapid CT or MRI imaging is mandatory to distinguish ischemic from hemorrhagic stroke before thrombolysis or thrombectomy. Prevalence of dementia is rising with population ageing, with the WHO recording nearly 10 million new cases each year, and the Alzheimer's Association estimating that about 7.2 million Americans aged 65 and older were living with Alzheimer's disease in 2025.

Brain tumors add further demand, with the International Agency for Research on Cancer (IARC) GLOBOCAN 2022 estimates recording about 322,000 new brain and central nervous system cancer cases. The WHO also estimates that around 50 million people live with epilepsy, many of whom require MRI to identify structural causes. These trends sustain high imaging volumes across hospitals and diagnostic centers.

Anti-Amyloid Therapies and Advances in Imaging Technology

New disease-modifying therapies and technology innovation are expanding the role of neuroimaging. The U.S. Food and Drug Administration (FDA) granted traditional approval to Leqembi (lecanemab) in July 2023 and approved Kisunla (donanemab) in July 2024 for early Alzheimer's disease. Both therapies require confirmation of amyloid pathology, frequently through amyloid PET, and serial MRI scans to monitor amyloid-related imaging abnormalities (ARIA), substantially increasing imaging per treated patient. In October 2023, the Centers for Medicare & Medicaid Services (CMS) removed its national coverage restriction limiting beta-amyloid PET scans, broadening patient access.

Technological advances are also improving diagnostic capability, including photon-counting CT such as Siemens Healthineers' NAEOTOM Alpha, deep learning image reconstruction that shortens MRI scan times, and ultra-high-field research systems. The FDA has authorized more than 1,000 AI-enabled medical devices, with radiology accounting for roughly three-quarters, supporting faster stroke triage and automated brain volumetry.

Restraints - High Equipment Costs, Helium Dependence, and Reimbursement Pressure

The high capital and operating costs of advanced neuroimaging systems restrain adoption, particularly in smaller hospitals and emerging economies. High-field MRI scanners, PET-CT, and PET-MRI systems require substantial upfront investment, dedicated shielded facilities, and costly service contracts. Conventional MRI magnets rely on liquid helium for cooling, and periodic global helium supply disruptions have increased operating costs and supply risk, prompting vendors to develop low-helium magnets such as Philips BlueSeal technology.

Reimbursement pressure further limits investment: the CMS Medicare Physician Fee Schedule conversion factor was reduced by about 2.83% for 2025, squeezing margins for imaging providers. PET imaging also depends on radiotracers with short half-lives, requiring access to cyclotrons and radiopharmacies. These cost and infrastructure barriers lengthen replacement cycles and constrain installations in price-sensitive markets.

Radiologist Shortages and Unequal Access to Imaging

Workforce shortages and uneven access to imaging infrastructure restrict market growth. The Royal College of Radiologists (RCR) reported in its 2024 workforce census that the U.K. faced a 30% shortfall of clinical radiologists, projected to widen to 40% by 2028 without intervention, causing reporting backlogs and delays. Similar shortages of radiologists, neuroradiologists, and technologists are reported in the United States and across Asia. Access to imaging is also highly unequal globally.

Data from the Organisation for Economic Co-operation and Development (OECD) show that Japan has more than 55 MRI units per million population and the United States close to 40, while the WHO Global Atlas of Medical Devices indicates that many low-income countries have fewer than one MRI unit per million people. Radiation exposure concerns associated with CT and nuclear imaging, especially in children, further encourage careful utilization and can moderate procedure volumes.

Opportunities - PET Imaging, Novel Radiotracers, and Alzheimer's Diagnostics

Rising demand for PET technology creates a significant opportunity for equipment manufacturers and radiopharmaceutical suppliers. PET imaging provides molecular-level information on amyloid plaques, tau tangles, glucose metabolism, and tumor activity that structural imaging cannot capture. Approved amyloid tracers such as Amyvid, Vizamyl, and Neuraceq, along with the tau tracer Tauvid approved by the FDA in May 2020, are central to diagnosing patients eligible for anti-amyloid therapies.

Industry investment in brain PET is accelerating, illustrated by Lantheus Holdings' agreement in January 2025 to acquire Life Molecular Imaging, developer of Neuraceq. Advanced scanners, including digital PET-CT systems and total-body PET such as United Imaging Healthcare's uEXPLORER, improve sensitivity, reduce scan times, and lower radiotracer doses, expanding clinical and research applications.

Portable, Low-Field, and AI-Enabled Neuroimaging

Increasing adoption of portable and AI-enabled imaging systems offers a major opportunity to extend neuroimaging beyond radiology departments and into underserved settings. Hyperfine's Swoop system became the first FDA-cleared portable, low-field MRI, enabling bedside brain imaging in intensive care units and emergency departments without moving critically ill patients. Mobile stroke units equipped with CT scanners are reducing time to treatment, and studies such as the BEST-MSU trial published in the New England Journal of Medicine in 2021 showed improved outcomes for patients treated in mobile stroke units.

Artificial intelligence is transforming workflows through automated detection of large vessel occlusion, hemorrhage, and brain atrophy, supporting faster treatment decisions and easing radiologist workloads. Low-cost, low-helium, and lightweight systems can make brain imaging accessible to the many regions lacking conventional MRI. Companies combining portable hardware, cloud-based AI analytics, and remote reporting services can capture new demand in emergency, critical care, and emerging-market settings.

Technology Insights

MRI is the leading technology category, holding around 38% of the brain imaging and neuroimaging market in 2026. Magnetic resonance imaging offers superior soft-tissue contrast without ionizing radiation, making it a preferred modality for evaluating brain tumors, multiple sclerosis, epilepsy, dementia, and subacute stroke. Advanced MRI techniques, including diffusion-weighted imaging, perfusion imaging, functional MRI, diffusion tensor imaging, and MR spectroscopy, provide detailed structural and functional information essential for surgical planning and disease monitoring.

Anti-amyloid therapies have further increased MRI demand, as patients receiving Leqembi or Kisunla require repeated scans to monitor amyloid-related imaging abnormalities (ARIA). Installed base density is high in developed markets, with OECD data identifying Japan and the United States among the leaders in MRI units per capita. Leading systems, including Siemens Healthineers' MAGNETOM, GE HealthCare's SIGNA, Philips' Ingenia, and Canon Medical's Vantage platforms, sustain the segment's leadership.

PET is the fastest-growing technology segment, projected to expand through 2033 as molecular imaging gains importance in Alzheimer's disease diagnosis, treatment selection, and oncology applications. The growing use of amyloid and tau PET tracers is improving the ability to identify disease-related changes in the brain and confirm eligibility for disease-modifying Alzheimer's therapies. Increasing adoption of digital PET scanners, which offer improved sensitivity and image quality, is further supporting segment growth.

Application Insights

Stroke is the leading application, holding an estimated 28% market share in 2026. Stroke requires immediate brain imaging for every suspected case, as non-contrast CT, CT angiography, CT perfusion, or MRI is essential to rule out hemorrhage, identify large vessel occlusions, and select patients for thrombolysis or mechanical thrombectomy. Guidelines from the American Heart Association (AHA) and American Stroke Association (ASA) recommend rapid imaging, with door-to-imaging targets measured in minutes, embedding neuroimaging in acute stroke protocols worldwide.

The World Stroke Organization reports that about one in four adults over the age of 25 is expected to experience a stroke in their lifetime, creating substantial imaging demand. Expansion of thrombectomy eligibility to extended time windows has increased the use of perfusion imaging and AI-based triage software.

Alzheimer's disease is the fastest-growing application, projected to register a CAGR of 7.4% through 2033, driven by anti-amyloid therapies, amyloid and tau PET imaging, and MRI safety monitoring. Increasing availability of disease-modifying treatments is creating greater demand for imaging to confirm amyloid pathology before treatment initiation and monitor patients for ARIA during therapy. Advances in PET tracers and quantitative MRI techniques are improving diagnostic assessment and treatment monitoring.

End-User Insights

Hospitals are the dominant end-user, capturing an estimated 57% market share in 2026. Hospitals manage acute neurological emergencies, including stroke, traumatic brain injury, and intracranial hemorrhage, requiring around-the-clock access to CT and MRI. The Centers for Disease Control and Prevention (CDC) reported about 69,000 traumatic brain injury-related deaths in the United States in 2021, highlighting the need for emergency neuroimaging. Hospitals also operate comprehensive stroke centers, neurosurgery departments, and oncology programs that depend on advanced imaging, including intraoperative MRI and PET/CT.

Large capital budgets enable investment in high-field MRI, photon-counting CT, and hybrid systems, while integration with hospital information systems supports multidisciplinary care. Hospitals are also primary sites for administering anti-amyloid infusions and conducting associated MRI monitoring.

Diagnostic centers are the fastest-growing end-user segment, projected to expand at a CAGR of 5.8% between 2026 and 2033 as outpatient imaging shifts from hospitals to lower-cost, high-throughput settings. The growing preference for convenient scheduling, shorter waiting times, and specialized imaging services is encouraging patients and healthcare providers to use independent diagnostic facilities. Investments in advanced MRI scanners, PET/CT systems, AI-assisted image analysis, and digital reporting are improving diagnostic center capabilities.

North America Brain Imaging and Neuroimaging Market Trends and Insights

North America is expected to lead the global brain imaging and neuroimaging market, accounting for a 38% share in 2026, supported by high imaging utilization, advanced healthcare infrastructure, and early adoption of new technologies. The region has a dense installed base of MRI, CT, and PET systems and a large network of comprehensive stroke centers certified by organizations such as The Joint Commission. Key regional trends include rapid growth in amyloid PET imaging and MRI monitoring associated with anti-amyloid therapies, broad adoption of AI-based stroke triage software, expansion of outpatient imaging centers, and early deployment of portable MRI systems in intensive care units.

Federal research investment through the National Institutes of Health (NIH) and its BRAIN Initiative, launched in 2013, supports advanced neuroimaging research. Canada contributes steady demand through publicly funded hospital systems and investments aimed at reducing diagnostic imaging wait times. Although reimbursement pressure remains a challenge, strong demand from neurology and oncology is expected to sustain regional leadership through 2033.

U.S. Brain Imaging and Neuroimaging Market Size

The U.S. brain imaging and neuroimaging market is projected to reach US$ 5.3 billion in 2026. The country has one of the highest MRI and CT densities among OECD members and very high imaging utilization rates. The Alzheimer's Association estimates that about 7.2 million Americans aged 65 and older are living with Alzheimer's disease. FDA approvals of Leqembi and Kisunla, combined with CMS coverage of amyloid PET imaging, are expanding imaging demand. The CDC reports that stroke is a leading cause of serious long-term disability, with more than 795,000 Americans experiencing a stroke each year. Opportunities lie in amyloid and tau PET imaging, AI-enabled stroke and dementia imaging software, portable MRI for critical care, and expansion of outpatient diagnostic imaging centers.

Europe Brain Imaging and Neuroimaging Market Trends and Insights

Europe is the second-largest regional market, accounting for an estimated 28% of global market share in 2026. Regional growth is supported by universal healthcare systems, an aging population, strong research institutions, and the presence of major manufacturers such as Siemens Healthineers and Philips. The European Stroke Organisation (ESO) and the Stroke Action Plan for Europe 2018–2030 promote access to rapid stroke imaging and thrombectomy, driving investment in CT and MRI capacity.

The European Medicines Agency (EMA) recommended marketing authorization for lecanemab in 2024, with restrictions, signaling growing demand for Alzheimer's imaging. Key regional trends include the adoption of helium-efficient MRI systems, AI-based image analysis, and expansion of PET-CT and PET-MRI capacity. The EU Artificial Intelligence Act, which entered into force in 2024, and the Medical Device Regulation (MDR) shape the deployment of AI-enabled imaging software. Healthcare systems are also investing in equipment replacement to address aging installed bases.

Germany Brain Imaging and Neuroimaging Market Size

Germany's market is estimated at US$ 1.0 billion in 2026. The country has one of the highest MRI and CT densities in Europe, according to OECD data, supported by an extensive hospital network and statutory health insurance coverage. Germany's aging population, with more than 22% of residents aged 65 or older according to Destatis, drives demand for stroke, dementia, and tumor imaging. The Hospital Future Act (KHZG) allocated about €4.3 billion for hospital digitalization, supporting investment in imaging IT and AI. Germany is home to Siemens Healthineers, a global leader in MRI, CT, and molecular imaging. Opportunities lie in replacing aging imaging equipment, expanding stroke unit networks, increasing PET imaging for Alzheimer's disease, and adopting AI-assisted neuroradiology solutions.

U.K. Brain Imaging and Neuroimaging Market Size

The U.K. brain imaging and neuroimaging market is estimated at US$ 710 million in 2026. The National Health Service (NHS) has been expanding diagnostic capacity in response to rising demand and long waiting lists, including the rollout of Community Diagnostic Centres (CDCs) recommended by the Richards Review in 2020. The Royal College of Radiologists reports a 30% shortfall of radiologists, accelerating the adoption of AI-based image analysis and remote reporting. The Stroke Association estimates that about 100,000 strokes occur in the U.K. each year, supporting demand for rapid CT and MRI imaging. The U.K. also leads in neuroimaging research through UK Biobank's imaging study, which aims to scan 100,000 participants. Opportunities exist in AI-enabled stroke triage, expanded MRI capacity in diagnostic centers, and Alzheimer's diagnostics.

France Brain Imaging and Neuroimaging Market Size

France accounts for an estimated 15% of European market revenue. The country's national health insurance system, Assurance Maladie, reimburses diagnostic imaging, supporting broad access to CT and MRI. France has historically had fewer MRI units per capita than some European peers, contributing to long waiting times that the government has sought to reduce through authorization of additional equipment. The Ségur de la Santé agreements of 2020 committed about €19 billion to hospital investment and modernization, including imaging infrastructure. France's national stroke plan has expanded the network of stroke units, while research institutions such as Inserm and NeuroSpin, home to an 11.7-tesla Iseult MRI scanner, lead advanced neuroimaging research. Opportunities lie in expanding MRI capacity, increasing PET imaging for dementia, and adopting AI-assisted neuroradiology.

Asia Pacific Brain Imaging and Neuroimaging Market Trends and Insights

Asia Pacific represents the fastest-growing regional market, projected to expand at a CAGR of 6.4% between 2026 and 2033. Growth is driven by rapidly aging populations, rising stroke and dementia burdens, expanding healthcare infrastructure, and government investment in medical equipment. China is the largest market in the region and has one of the world's highest stroke burdens. In March 2024, China's State Council launched a large-scale equipment renewal action plan that includes upgrading medical imaging equipment in hospitals, boosting demand for MRI and CT systems.

Domestic manufacturers such as United Imaging Healthcare and Neusoft Medical Systems are expanding their market share with cost-competitive and high-end systems, including ultra-high-field MRI. Key regional trends include rapid adoption of AI imaging software, growth of independent imaging centers, and increasing PET-CT installations across China, South Korea, and Australia, collectively broadening access to advanced neuroimaging.

India Brain Imaging and Neuroimaging Market Size

India's brain imaging and neuroimaging market is estimated at about US$ 350 million in 2026. India faces a rising burden of stroke, traumatic brain injury from road traffic accidents, and dementia as its population ages. The Ministry of Road Transport and Highways reported more than 170,000 road accident deaths in 2023, with many incidents involving head injuries requiring CT imaging. Government initiatives such as Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PM-JAY) are expanding access to hospital care, while the Production Linked Incentive (PLI) scheme for medical devices encourages domestic manufacturing of imaging equipment. Rapid growth in private hospital chains and diagnostic center networks supports demand. Opportunities exist in affordable CT and MRI systems, teleradiology, and AI-based stroke imaging.

Japan Brain Imaging and Neuroimaging Market Size

Japan's market is estimated at US$ 930 million in 2026. Japan has the highest MRI and CT densities among OECD countries, and its population is the world's oldest, with about 29% of residents aged 65 or older, according to the Statistics Bureau of Japan. More than 4 million people in Japan are estimated to be living with dementia, and the Basic Act on Dementia, enacted in 2023, prioritizes early diagnosis and care. Japan's Ministry of Health, Labour and Welfare (MHLW) approved lecanemab in September 2023, increasing demand for amyloid PET imaging and MRI monitoring. Domestic leaders such as Canon Medical Systems, Fujifilm Healthcare, and Shimadzu drive innovation. Opportunities lie in replacing aging installed equipment, adopting AI-based reading support, and expanding Alzheimer's diagnostics.

Southeast Asia Brain Imaging and Neuroimaging Market Size

Southeast Asia is an emerging market, accounting for nearly 7% of Asia Pacific market revenue. Stroke is a leading cause of death in several countries in the region, including Indonesia, Thailand, and Vietnam, driving demand for CT and MRI capacity in hospitals. Expansion of universal health coverage programs, such as Indonesia's Jaminan Kesehatan Nasional (JKN) and Thailand's Universal Coverage Scheme, is improving access to diagnostic imaging. Governments are investing in hospital infrastructure and stroke networks, while Singapore and Malaysia serve as regional hubs for advanced neuroimaging, medical tourism, and research. Private hospital groups are expanding PET-CT and high-field MRI services in major cities. Vendors offering affordable, low-helium MRI systems, refurbished equipment, teleradiology, and service support are well positioned to capture rising demand.

The global brain imaging and neuroimaging market is moderately consolidated, with a few global manufacturers, including Siemens Healthineers, GE HealthCare, Philips, Canon Medical Systems, and Fujifilm Healthcare, holding a significant share of MRI, CT, and PET installations through broad portfolios, global service networks, and strong hospital relationships. Fujifilm strengthened its position by acquiring Hitachi's diagnostic imaging business in 2021. Chinese manufacturers such as United Imaging Healthcare and Neusoft Medical Systems are expanding rapidly, while specialists including Bruker, Mediso, MR Solutions, Esaote, Shimadzu, and Hyperfine compete in preclinical, dedicated, and portable imaging.

Market leaders differentiate through AI-enabled image reconstruction, helium-efficient magnets, photon-counting CT, and digital PET. Key strategies include partnerships with radiopharmaceutical companies, software and AI acquisitions, and expansion in emerging markets. Emerging business models include imaging-as-a-service, managed equipment services, and subscription-based AI software.

Key Industry Developments

• In January 2025, Lantheus Holdings, Inc. announced an agreement to acquire Life Molecular Imaging, developer of the amyloid PET tracer Neuraceq, strengthening its radiopharmaceutical portfolio for Alzheimer's disease diagnosis amid rising demand for brain PET imaging.
• In August 2024, GE HealthCare received FDA 510(k) clearance for SIGNA MAGNUS, a head-only 3.0T MRI system featuring high-performance gradients designed for advanced neuroimaging and research applications, including detailed brain microstructure and functional imaging.
• In July 2024, Eli Lilly and Company received FDA approval for Kisunla (donanemab) for early symptomatic Alzheimer's disease, requiring confirmation of amyloid pathology and MRI monitoring, expanding demand for amyloid PET and brain MRI services.